Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BioCryst Pharmaceuticals Q4 2025 Earnings Call - ORLADEYO drove record profitability as navenibart aims to own HAE prophylaxis
BioCryst closed 2025 with ORLADEYO revenue of $601.8 million, a 38% year on year increase and 43% growth excluding the divested European business, and posted a non-GAAP operating profit of $214 millio...
- ORLADEYO delivered full-year 2025 revenue of $601.8 million, up 38% year on year, and up 43% when excluding the European business sold in October.
- BioCryst reported a record non-GAAP operating profit of $214 million in 2025, a 198% increase year on year after stripping out Europe and one-time items.
- Management is repositioning BioCryst as a profitable, rare disease company focused on a portfolio approach to HAE prophylaxis, not a single-product defense.
- +16 more takeaways
Arbe Robotics Q4 2025 Earnings Call - Strategic Pivot to Defense, Robotaxi and Non-Auto Markets as CEO Transition Extends Runway
Arbe used this quarter to acknowledge what many already felt, and then acted. Management is broadening the commercial focus away from a sole reliance on Western passenger OEMs toward faster-adopting m...
- Strategic pivot: Arbe is broadening focus beyond Western passenger OEMs to prioritize Chinese OEMs, defense, homeland security, robotaxi/robotruck, marine safety and smart infrastructure where adoption cycles are shorter.
- Leadership change: Ram Machness will become CEO on April 1, 2026. Kobi Marenko transitions to President to focus on long-term strategy and defense partnerships.
- Balance sheet strengthened: Cash and equivalents were $45.0 million at December 31, 2025, and the company raised $18.5 million in an underwritten public offering in January 2026.
- +15 more takeaways
Warby Parker Inc. 4Q 2025 Earnings Call - Act Three is AI: 2026 launch planned but revenue excluded from guidance
Warby Parker closed fiscal 2025 with solid growth and its first full year of net income, but the call felt like a dress rehearsal for something bigger. Management outlined an ambitious pivot into AI g...
- Warby Parker reported fiscal 2025 revenue of $871.9 million, up 13% year-over-year, with full-year adjusted EBITDA of $95 million, up 30%, and free cash flow of $44 million.
- The company delivered its first full year of net income in 2025 and ended the year with $286 million in cash, plus a $120 million credit facility (expandable to $175 million).
- Management announced Act Three: a planned launch of AI glasses in 2026 in partnership with Google and Samsung, positioning the company to move from traditional eyewear to intelligent eyewear.
- +13 more takeaways
ADTRAN Holdings Q4 2025 Earnings Call - Optical Surge Drives Revenue, Margins and Cash Flow Recovery
ADTRAN delivered a clean quarter of execution. Q4 revenue of $291.6 million beat expectations, driven by a 33% year-over-year leap in optical networking and broad-based growth across access, aggregati...
- Q4 revenue $291.6 million, up 20% year-over-year and 4% sequentially, above the high end of guidance.
- This was the sixth consecutive quarter of sequential growth and the fifth consecutive quarter of year-over-year improvement.
- U.S. revenue led the quarter, rising 31% year-over-year and 14% sequentially; non-U.S. revenue grew 12% year-over-year and declined 3% sequentially due to ordering patterns among large European customers.
- +17 more takeaways
Integra LifeSciences Q4 2025 Earnings Call - Quality and Supply Fixes Drive Cautious 2026 Recovery Plan
Integra closed 2025 having made visible progress on quality, compliance, and supply reliability, but the company is deliberately conservative about near-term growth while remediation and tariff uncert...
- Q4 2025 revenue was $435 million, adjusted EPS $0.83, both above the midpoint of guidance; sequential revenue improved by $33 million versus Q3.
- Full-year 2025 revenue was $1.635 billion, up 1.5% reported but down 0.7% on an organic basis, with Acclarent acquisition a key contributor to reported growth.
- Organic performance was hampered by quality remediation and supply constraints, notably in Tissue Technologies where Q4 revenue fell 12.8% (MediHoney remediation and tough Integra Skin comps were main drivers).
- +12 more takeaways
Hafnia Q4 2025 Earnings Call - Strong quarter and strategic push toward a TORM combination
Hafnia closed 2025 on a strong note, reporting Q4 net profit of $109.7 million and full-year net profit of $339.7 million. The company is returning capital aggressively, declaring an 80% payout for Q4...
- Q4 net profit $109.7 million, full-year 2025 net profit $339.7 million; Q4 was the strongest quarter of 2025 for Hafnia.
- Hafnia acquired 13.97% of TORM from Oaktree and is engaging with stakeholders to explore a potential combination, citing strategic, commercial and financial synergies.
- Dividend policy remains explicit and cash returns are large: 80% payout for Q4 equals $87.7 million, full-year dividends $271.7 million, implied yield about 10% for 2025.
- +13 more takeaways
Playtika Holding Corp Q4 2025 Earnings Call - D2C Hits $1 Billion Run Rate as SuperPlay Rewrites the Mix
Playtika closed 2025 with a clear strategic pivot: direct-to-consumer (D2C) and casual SuperPlay titles are reshaping revenue mix and cash generation, even as GAAP results took a big one-time hit from...
- Q4 2025 revenue was roughly $678.8 million, with Adjusted EBITDA of $201.4 million.
- Direct-to-consumer (D2C) reached a ~$1 billion annual run rate and represented 36.8% of Q4 revenue, a central part of management’s multi-channel strategy.
- Casual games now account for about 74% of Playtika’s revenue, reflecting a multi-year mix shift away from reliance on social casino titles.
- +12 more takeaways
Stellantis Full Year 2025 Earnings Call - Decisive Reset Returned H2 Growth; 2026 Is Year of Execution
Stellantis framed 2025 as a year of reset and paid the near-term cost. The company returned to top-line growth in H2 2025 after product and commercial fixes, but the income statement still shows the d...
- Company view: 2025 was a deliberate reset year, H2 showed return to top-line growth and early benefits from actions taken.
- Full-year results: consolidated shipments 5.5 million units (+1%), net revenues EUR 153 billion (-2%), AOI margin negative 0.5%, industrial free cash flow outflow EUR 4.5 billion.
- H2 improvement: H2 net revenues growth and pricing gains (net pricing +2% in H2 North America) helped drive a sequential recovery; H2 industrial FCF was negative EUR 1.5 billion, a 50% sequential improvement and 73% YoY improvement.
- +15 more takeaways
Cronos Group Q4 2025 Earnings Call - Record 2025, Spinach vape breakout and Netherlands acquisition
Cronos closed 2025 with its strongest year yet, reporting record net revenue, gross profit, and Adjusted EBITDA while growing organically by 25%. The fourth quarter accelerated that momentum, with con...
- Cronos reported a record 2025, growing net revenue organically by 25% year-over-year and posting record full-year gross profit and Adjusted EBITDA.
- Q4 2025 consolidated net revenue was $44.5 million, up 47% year-over-year, driven by higher flower sales in Israel and Canada and stronger Canadian extract sales.
- Spinach was the company standout in Canada, becoming the number 2 overall vape brand in December and the number 1 vape cartridge brand in Q4, led by Cherry Crush and Blueberry Dynamite.
- +11 more takeaways
Dorman Products Fourth Quarter 2025 Earnings Call - Tariff timing to pressure early 2026 margins, but company guides 7%-9% sales growth
Dorman reported a solid 2025 on the top line and margins, but the call read like a company still wrestling with trade policy aftershocks. Full-year sales hit $2.13 billion, up 6%, and adjusted EPS ros...
- 2025 full-year net sales $2.13 billion, up 6% year-over-year; Q4 net sales $538 million, up about 1% versus prior year.
- Adjusted diluted EPS for 2025 was $8.87, a 24% increase year-over-year; Q4 adjusted diluted EPS was $2.17, down 1% versus a very strong Q4 2024.
- Tariffs remain the dominant narrative. Management estimates incremental tariffs reduced 2025 adjusted EPS by approximately $1.25.
- +14 more takeaways